Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Starting too early introduces unnecessary risk during a vulnerable recovery period
Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials
477 Additionally, vascular changes, hormonal imbalances, and psychological factors contribute to genitourinary dysfunction in diabetes
See www.pureencapsulations.com for information about the relationship between this product and any claims made
Activating GLP-1 receptors has been shown to aid weight loss, glycemic control, cardiovascular health, liver health, neurological function, and more
Novo Nordisk) or tirzepatide (Mounjaro, Zepbound
US$ 27.66
US$ 25.90
US$ 26.70
US$ 20.35
US$ 26.37
US$ 24.10
